The 21 breast cancers from 19 heterozygous LoF variant carrier cases were predominantly high-grade, invasive, ductal carcinomas (19/21) and hormone receptor-positive (16/21) of which three had ERBB2 amplification (HER2+). Here, ERBB2 is linked to breast carcinoma.